Last updated: July 27, 2026
Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited, U.S. District Court (1:22-cv-00114), is a Hatch-Waxman patent dispute tied to Mylan’s generic-candidate entry. The case is pending in the federal docket for the Eastern District of Texas, and the available public information in this prompt does not include the specific asserted patent numbers, claims, product (NDC/strength/form), venue judge assignment, procedural posture (motions/Markman/trial), or any settlement/consent decree terms. Without those core docket and Orange Book artifacts, a complete and accurate infringement and patent-estate analysis cannot be produced.
What are the case details for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited 1:22-cv-00114?
Answer (what is required for an infringement analysis): A correct litigation summary depends on the complaint and any amended pleadings identifying (i) the asserted patents, (ii) the accused Mylan product, (iii) the filing details of Mylan’s ANDA (or application number and Paragraph IV certifications), (iv) the requested relief, and (v) the asserted theory for each patent (infringement and any invalidity defenses).
What court, judge, and timing matter for 1:22-cv-00114?
A litigation analysis also requires:
- Filing date and any consolidation
- Case management order milestones (initial disclosures, claim construction, expert schedule)
- Whether a Markman hearing occurred
- Status of dispositive motions (12(b)(6), summary judgment)
- Any litigation stays tied to FDA approval or related proceedings
What docket items drive the patent scope view?
For high-stakes assessment, the key filings are typically:
- Complaint (asserted patents and infringement charts)
- Answer and counterclaims (invalidity contentions)
- Claim construction order
- Summary judgment rulings
- Settlement agreement or Rule 41 dismissal (if applicable)
- Final judgment if the case reached merits
Which patents does Otsuka assert against Mylan in 1:22-cv-00114?
Answer: The asserted patent list is the minimum necessary input to provide a precise summary of infringement and validity issues. The prompt does not contain the asserted patent numbers or their titles/claims, so no patent-by-patent analysis can be made.
How to structure the patent estate read when the asserted patents are known
Once the asserted patents are identified, analysis usually breaks down into:
- Independent claim type (composition, formulation, method-of-use, manufacturing)
- Claim dependencies (dependent claim fallbacks)
- Claim construction themes (e.g., solvate/polymorph definitions, release-rate limitations, patient population restrictions)
- Expected invalidity grounds (35 U.S.C. §101, §102/§103, §112)
- Common infringement gating elements (specific excipients, dosing regimen, release profile, or therapeutic use)
Where “Paragraph IV” certification affects the scope
Hatch-Waxman Paragraph IV cases are anchored to:
- The Orange Book listing(s) referenced by the ANDA
- The certification type (P-IV) for each listed patent
- The “effective date” framework tying to FDA approval
Without the Orange Book listing map for this case, patent scope can’t be tied to the specific ANDA.
What does Mylan accuse Otsuka of in invalidity defenses in 1:22-cv-00114?
Answer: A correct invalidity analysis requires the invalidity contentions. Those are not present in the prompt.
Typical defenses to parse once pleadings are available
Once the record is available, litigation analysis normally addresses:
- Anticipation and obviousness based on the closest prior art references
- Enablement and written description challenges for dosage/formulation/method claims
- §101 arguments if the asserted patents are method-of-treatment claims or contain functional limitations
- Definiteness issues for claim terms that construe differently across districts
What stage is 1:22-cv-00114 in, and what does that mean for generic entry timing?
Answer: Docket stage determines whether the case is driving (i) immediate launch risk or (ii) longer-term injunction risk or settlement dynamics.
Key timing questions the docket answers
To determine exposure, the analysis must know:
- Is there an active preliminary injunction or TRO?
- Has FDA approval occurred for the Mylan ANDA?
- Has the court issued a claim construction order that narrows infringement?
- Are there summary judgment rulings affecting enforceability or infringement?
Exclusivity interaction: 180-day exclusivity and launch triggers
A Hatch-Waxman case can affect launch timing via:
- Statutory 180-day exclusivity (or loss thereof)
- Court findings of infringement or invalidity
- Settlement triggers and agreed “at-risk” launch provisions
Without the case specifics, exclusivity timing cannot be computed.
How does Otsuka’s patent estate compare with Mylan’s ability to design around?
Answer: Design-around analysis depends on:
- The claim language actually construed by the court
- The “essential elements” identified in infringement contentions
- Whether asserted claims are composition/formulation or method-of-use
Design-around levers to evaluate once claims are known
For typical Otsuka portfolios, design-around themes often include:
- Switching excipient systems or changing release kinetics to avoid composition limitations
- Changing particle size, salt form, polymorph, or solvate form if those are claimed
- Changing dosing regimen or patient eligibility criteria for method-of-use claims
- Changing manufacturing method steps if manufacturing patents are asserted
No such claim elements are available in the prompt.
What settlements or injunction outcomes exist for Otsuka v. Mylan 1:22-cv-00114?
Answer: Settlement and injunction outcomes require docket confirmation of any:
- Stipulated dismissal (with or without prejudice)
- Consent judgment
- Court-entered injunction
- Public settlement press release or SEC filing
The prompt does not provide settlement/injunction information.
What FDA regulatory status matters for the accused Mylan product?
Answer: Hatch-Waxman litigation is tied to the ANDA product’s:
- Approval status (pending vs approved)
- Indication(s) and strength/form (tablet, capsule, oral suspension, etc.)
- Labeling carve-outs and Paragraph IV certification mapping to Orange Book patents
No FDA or Orange Book details appear in the prompt.
Key Takeaways
- A litigation summary and patent-strength analysis for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (1:22-cv-00114) cannot be completed from the information provided in this prompt.
- A correct high-stakes assessment requires the asserted patent numbers, the accused product identity, and the procedural posture from docket filings and the complaint.
- Those missing inputs prevent accurate coverage of infringement theories, invalidity defenses, claim construction outcomes, injunction/settlement status, and generic launch timing.
FAQs
- What filings in a Hatch-Waxman case control the asserted patent scope and infringement theory?
- How do claim construction orders usually change risk for a Paragraph IV ANDA defendant?
- What role do Orange Book patent listings play in determining whether a case covers composition versus method-of-use?
- When does 180-day exclusivity most commonly drive settlement outcomes in generic litigation?
- What docket milestones indicate a case is likely headed toward trial versus early resolution?
References
- U.S. District Court docket: Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited, No. 1:22-cv-00114.
